7.21
price down icon4.25%   -0.32
pre-market  Pre-market:  7.24   0.03   +0.42%
loading
Verastem Inc stock is traded at $7.21, with a volume of 700.57K. It is down -4.25% in the last 24 hours and up +18.00% over the past month. Verastem Inc is late-stage development biopharmaceutical company, committed to advancing new medicines for patients battling cancer. Its pipeline is focused on novel anticancer agents that inhibit critical signaling pathways in cancer that promote cancer cell survival and tumor growth, particularly RAF/MEK inhibition and FAK inhibition.
See More
Previous Close:
$7.53
Open:
$7.46
24h Volume:
700.57K
Relative Volume:
0.57
Market Cap:
$320.89M
Revenue:
$3.64M
Net Income/Loss:
$-87.37M
P/E Ratio:
-1.7543
EPS:
-4.11
Net Cash Flow:
$-86.46M
1W Performance:
+3.59%
1M Performance:
+18.00%
6M Performance:
+156.58%
1Y Performance:
-32.87%
1-Day Range:
Value
$7.06
$7.57
1-Week Range:
Value
$6.6706
$7.59
52-Week Range:
Value
$2.10
$13.52

Verastem Inc Stock (VSTM) Company Profile

Name
Name
Verastem Inc
Name
Phone
(781) 292-4200
Name
Address
117 KENDRICK STREET, NEEDHAM, MA
Name
Employee
73
Name
Next Earnings Date
2024-11-06
Name
Latest SEC Filings
Name
VSTM's Discussions on Twitter

Compare VSTM with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
Biotechnology icon
VSTM
Verastem Inc
7.21 320.89M 3.64M -87.37M -86.46M -4.11
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
502.92 129.14B 11.02B -535.60M -978.00M -2.20
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
680.61 74.41B 14.20B 4.41B 3.54B 38.28
Biotechnology icon
ARGX
Argen X Se Adr
581.21 35.31B 2.19B 833.04M -1.28B 12.71
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
241.75 31.30B 2.25B -278.16M -42.59M -2.17
Biotechnology icon
ONC
Beigene Ltd Adr
254.57 27.35B 3.32B -860.46M -1.04B -8.32

Verastem Inc Stock (VSTM) Upgrades & Downgrades

Date Action Analyst Rating Change
Dec-31-24 Reiterated BTIG Research Buy
Sep-30-24 Initiated Guggenheim Buy
Nov-21-23 Resumed BTIG Research Buy
Sep-27-23 Initiated B. Riley Securities Buy
Jun-15-23 Upgrade Mizuho Neutral → Buy
Sep-07-22 Resumed Alliance Global Partners Buy
Apr-29-22 Resumed Cantor Fitzgerald Overweight
Apr-14-22 Initiated RBC Capital Mkts Outperform
Mar-09-22 Initiated Truist Buy
Jul-01-21 Initiated Alliance Global Partners Buy
May-24-21 Upgrade BTIG Research Neutral → Buy
Jun-20-19 Downgrade BTIG Research Buy → Neutral
May-10-19 Downgrade Raymond James Outperform → Mkt Perform
Jul-13-18 Initiated BTIG Research Buy
May-02-18 Initiated Seaport Global Securities Buy
Mar-08-18 Initiated B. Riley FBR, Inc. Buy
Sep-07-17 Reiterated H.C. Wainwright Buy
Apr-13-17 Initiated Oppenheimer Outperform
Mar-24-17 Reiterated H.C. Wainwright Buy
Sep-29-15 Downgrade Cantor Fitzgerald Buy → Hold
Sep-29-15 Downgrade JMP Securities Mkt Outperform → Mkt Perform
Sep-29-15 Downgrade Jefferies Buy → Hold
Sep-29-15 Downgrade Raymond James Strong Buy → Outperform
Sep-28-15 Downgrade Mizuho Buy → Neutral
Sep-28-15 Downgrade ROTH Capital Buy → Neutral
Sep-09-15 Initiated Raymond James Strong Buy
May-12-15 Reiterated UBS Buy
Apr-08-15 Initiated H.C. Wainwright Buy
Jan-23-15 Reiterated ROTH Capital Buy
Jul-08-14 Resumed Oppenheimer Perform
Feb-11-14 Initiated Mizuho Buy
View All

Verastem Inc Stock (VSTM) Latest News

pulisher
Mar 13, 2025

Verastem to Present at Keystone Symposia on PI3 Kinase - AOL

Mar 13, 2025
pulisher
Mar 11, 2025

Verastem: Upcoming PDUFA, But I Remain Cautious (NASDAQ:VSTM) - Seeking Alpha

Mar 11, 2025
pulisher
Mar 11, 2025

Rhumbline Advisers Acquires 10,352 Shares of Verastem, Inc. (NASDAQ:VSTM) - Defense World

Mar 11, 2025
pulisher
Mar 08, 2025

Why the Global Cancer Market Could Surpass $900 Billion-And the Stocks Leading the Charge - The Malaysian Reserve

Mar 08, 2025
pulisher
Mar 08, 2025

Why the Global Cancer Market Could Surpass $900 Billion--And the Stocks Leading the Charge - Benzinga

Mar 08, 2025
pulisher
Mar 06, 2025

Verastem (VSTM) Expected to Announce Earnings on Thursday - Defense World

Mar 06, 2025
pulisher
Mar 06, 2025

Objective long/short (VSTM) Report - Stock Traders Daily

Mar 06, 2025
pulisher
Mar 05, 2025

Verastem Inc (NASDAQ: VSTM) Stock Forecast: Bearish Expectations Portend -120.34% Downside In 2025 - Stocks Register

Mar 05, 2025
pulisher
Mar 04, 2025

Verastem (NASDAQ:VSTM) Stock Price Passes Above 200 Day Moving Average – Should You Sell? - Defense World

Mar 04, 2025
pulisher
Feb 23, 2025

Verastem, Inc. (NASDAQ:VSTM) Given Consensus Rating of “Buy” by Brokerages - Defense World

Feb 23, 2025
pulisher
Feb 20, 2025

Verastem Oncology Announces Multiple Data Presentations At Society Of Gynecologic Oncology 2025 Annual Meeting On Women's Cancer - Marketscreener.com

Feb 20, 2025
pulisher
Feb 20, 2025

Verastem Oncology Announces Multiple Data Presentations at Society of Gynecologic Oncology 2025 Annual Meeting on Women’s Cancer - Business Wire

Feb 20, 2025
pulisher
Feb 20, 2025

Can This New Ovarian Cancer Drug Transform Treatment? Key Data Reveals Breakthrough Potential - StockTitan

Feb 20, 2025
pulisher
Feb 19, 2025

VSTM Up as NDA for Ovarian Cancer Combo Gets FDA's Priority Review Tag - MSN

Feb 19, 2025
pulisher
Feb 13, 2025

When the Price of (VSTM) Talks, People Listen - Stock Traders Daily

Feb 13, 2025
pulisher
Feb 10, 2025

Financial Snapshot: Analyzing Verastem Inc (VSTM)’s Key Ratio Metrics - The Dwinnex

Feb 10, 2025
pulisher
Feb 08, 2025

Verastem Inc (NASDAQ: VSTM) Shares Fall By -4.77 Percent In The Past Week, But How Long Will It Last? - Marketing Sentinel

Feb 08, 2025
pulisher
Feb 06, 2025

The time has not yet come to remove your chips from the table: Verastem Inc (VSTM) - SETE News

Feb 06, 2025
pulisher
Feb 05, 2025

Recent Insider Activity Could Benefit Verastem Inc (VSTM) - Knox Daily

Feb 05, 2025
pulisher
Feb 05, 2025

Verastem CEO Dan Paterson sells shares worth $4,890 - MSN

Feb 05, 2025
pulisher
Feb 05, 2025

Verastem CEO Dan Paterson sells shares worth $4,890 By Investing.com - Investing.com Canada

Feb 05, 2025
pulisher
Feb 05, 2025

Verastem, Inc. (NASDAQ:VSTM) Shares Acquired by JPMorgan Chase & Co. - Defense World

Feb 05, 2025
pulisher
Feb 04, 2025

Verastem (NASDAQ:VSTM) Given New $9.00 Price Target at B. Riley - MarketBeat

Feb 04, 2025
pulisher
Feb 04, 2025

Verastem, Inc. (NASDAQ:VSTM) Sees Large Increase in Short Interest - MarketBeat

Feb 04, 2025
pulisher
Feb 04, 2025

Financial Metrics Check: Verastem Inc (VSTM)’s Ratios for Trailing Twelve Months - The Dwinnex

Feb 04, 2025
pulisher
Feb 02, 2025

B. Riley Forecasts Strong Price Appreciation for Verastem (NASDAQ:VSTM) Stock - Defense World

Feb 02, 2025
pulisher
Feb 01, 2025

Brokerages Set Verastem, Inc. (NASDAQ:VSTM) PT at $13.38 - MarketBeat

Feb 01, 2025
pulisher
Feb 01, 2025

Vanguard Group Inc. Increases Stake in Verastem Inc. - GuruFocus.com

Feb 01, 2025
pulisher
Jan 31, 2025

Verastem price target raised to $9 from $7 at B. Riley - MSN

Jan 31, 2025
pulisher
Jan 31, 2025

B. Riley Adjusts Verastem's Price Target to $9 From $7, Maintains Buy Rating -January 31, 2025 at 09:19 am EST - Marketscreener.com

Jan 31, 2025
pulisher
Jan 31, 2025

Short Interest in Verastem, Inc. (NASDAQ:VSTM) Increases By 59.5% - Armenian Reporter

Jan 31, 2025
pulisher
Jan 31, 2025

Verastem Licenses Investigational Cancer Drug VS-7375 from GenFleet, Shares Rise 4.1% – Market - HPBL

Jan 31, 2025
pulisher
Jan 29, 2025

Verastem Oncology to Present at the Guggenheim SMID Cap Biotech Conference - Yahoo Finance

Jan 29, 2025
pulisher
Jan 29, 2025

Verastem's Next Big Move: Key Revelations Expected at Major Biotech Conference - StockTitan

Jan 29, 2025
pulisher
Jan 27, 2025

Verastem Exercises Option for VS-7375 Targeting RAS Pathway Driven CancersVerastem, Inc. (NASDAQ:VSTM) has announced the exercise of its option with regards to VS-7375, which is an oral and selective KRAS G12D (ON/OFF) inhibitor. This move signif - Defense World

Jan 27, 2025
pulisher
Jan 26, 2025

Guggenheim Reiterates Buy Rating for Verastem (NASDAQ:VSTM) - Defense World

Jan 26, 2025
pulisher
Jan 25, 2025

Verastem's (VSTM) Buy Rating Reaffirmed at Guggenheim - MarketBeat

Jan 25, 2025
pulisher
Jan 25, 2025

Mizuho maintains Verastem stock outperform with $9 target By Investing.com - Investing.com Australia

Jan 25, 2025
pulisher
Jan 24, 2025

Mizuho maintains Verastem stock outperform with $9 target - MSN

Jan 24, 2025
pulisher
Jan 24, 2025

Cantor Fitzgerald Estimates Verastem FY2025 Earnings - Defense World

Jan 24, 2025
pulisher
Jan 23, 2025

Verastem Stock Soars 46% After FDA Grants Priority Review for Cancer Treatment – Market - HPBL

Jan 23, 2025
pulisher
Jan 23, 2025

Cantor Fitzgerald Forecasts Verastem FY2025 Earnings - MarketBeat

Jan 23, 2025
pulisher
Jan 23, 2025

Verstem avutometinib and defactinib combo gains FDA priority review - Seeking Alpha

Jan 23, 2025
pulisher
Jan 23, 2025

Verastem Expands Oncology Pipeline with VS-7375 Acquisition - TipRanks

Jan 23, 2025
pulisher
Jan 23, 2025

Verastem Oncology Outlines 2025 Strategic Priorities and Milestones for Novel Pipeline Targeting RAS/MAPK Pathway-Driven Cancers - Business Wire

Jan 23, 2025

Verastem Inc Stock (VSTM) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading
$75.07
price up icon 1.39%
$305.39
price down icon 0.55%
$19.19
price down icon 3.62%
$32.68
price down icon 0.52%
$97.47
price down icon 2.84%
biotechnology ONC
$254.57
price up icon 1.89%
Cap:     |  Volume (24h):